Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Address: Amgen Ltd. Klimentská 46 110 02 Prague 1,Czech Republic
Tel: +420 221 773 500
Web: http://www.amgen.cz/
Amgen commenced operations in Central and Eastern Europe on 1 May 2004, when the first eight countries of the region became members of the EU. Since then, Amgen’s Central European activities have constantly expanded. Among the company’s focus markets in the region are the Czech Republic, Poland, Hungary, Slovakia and Romania. Amgen is also active in Lithuania, Latvia, Estonia, Slovenia, Bulgaria.Amgen entered the Czech market in May 2004.The company is headquartered in Prague, but its team covers the whole territory of the Republic. At present, the Czech branch has over 60 employees.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Mr. Kužela, you have a very interesting background: from 1993 until 2011, you variously worked for the Staropramen beer factory and its parent organization, StarBev. You identify yourself as an…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
Dr. Heger, you were appointed as the Czech Minister of Health in July of 2010. What challenges did you see for the Czech healthcare system, and what has been your…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Mr. Krejčí, can you please begin with a broad introduction to Ewopharma, for those of our readers who are unfamiliar with the company? Ewopharma is part of a large group…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of…
Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its…
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
See our Cookie Privacy Policy Here